Want to see ZBH full AI Analyst Report?
ZBH Stock Chart & Stats
$91.35
$1.70(1.90%)
At close: 4:00 PM EDT
$91.35
$1.70(1.90%)
Day’s Range― - ―
52-Week Range$79.12 - $108.29
Previous CloseN/A
Volume1.25M
Average Volume (3M)2.13M
Market Cap
$18.17B
Enterprise Value$24.76K
Total Cash (Recent Filing)$424.20M
Total Debt (Recent Filing)$7.47B
Price to Earnings (P/E)24.3
Beta0.49
Next Earnings
Nov 04, 2026EPS Estimate
1.88Next Dividend Ex-DateN/A
Dividend Yield1.02%
Share Statistics
EPS (TTM)3.87
Shares Outstanding193,462,480
10 Day Avg. Volume2,210,838
30 Day Avg. Volume2,130,373
Financial Highlights & Ratios
PEG Ratio-1.26
Price to Book (P/B)1.40
Price to Sales (P/S)2.16
P/FCF Ratio12.09
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$100.22Price Target Upside9.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)8.49
Revenue Forecast (FY)$8.55B
Bulls Say, Bears Say
Bulls Say
High Gross And EBITDA MarginsSustained high gross and EBITDA margins indicate durable operating leverage and pricing/production efficiency in implant and consumable portfolios. That margin buffer supports continued R&D and robotics investment, cushions against modest price erosion, and helps fund capital returns and M&A over the medium term.
Robotics And Technology MomentumAccelerating adoption of robotics, digital tools and high‑margin consumables shifts revenue mix toward recurring and higher‑growth areas. Completion of Monogram enrollment and strong ROSA/TMINI uptake underpin a multi‑year commercial ramp, expanding addressable market and creating stickier surgeon/hospital relationships.
Improved Liquidity And Credit FlexibilityProactive refinancing expands available liquidity and preserves strategic optionality for acquisitions, working capital, and share repurchases. Five‑year facility with covenant room provides resilience against cyclical shocks and supports multi‑year investments in robotics and international go‑to‑market shifts.
Bears Say
Compressed Net Margin And Weak ROEFalling net margins and weakened ROE signal reduced bottom‑line efficiency versus prior years, limiting returns on invested capital. Even with strong gross margins, pressure on net income reduces retained earnings growth and constrains long‑term capital allocation flexibility and shareholder returns.
Negative Free Cash Flow Growth And Cash VolatilitySharp negative FCF growth and operating cash flow variability suggest working‑capital or timing pressures that undermine consistent cash conversion. This raises risk to funding buybacks, debt service, and robotics rollouts if operating momentum weakens, and increases sensitivity to any margin deterioration.
Commercial Transition And Product HeadwindsA multi‑year U.S. salesforce transformation and legacy knee phase‑out create persistent execution risk as account relationships and surgeon preference can shift. Lost large accounts and underperformance in key portfolios may allow competitors to gain share, slowing durable revenue recovery during the transition.
Zimmer Biomet Holdings News
ZBH FAQ
What was Zimmer Biomet Holdings’s price range in the past 12 months?
Zimmer Biomet Holdings lowest stock price was $79.12 and its highest was $108.29 in the past 12 months.
What is Zimmer Biomet Holdings’s market cap?
Zimmer Biomet Holdings’s market cap is $18.17B.
When is Zimmer Biomet Holdings’s upcoming earnings report date?
Zimmer Biomet Holdings’s upcoming earnings report date is Nov 04, 2026 which is in 91 days.
How were Zimmer Biomet Holdings’s earnings last quarter?
Zimmer Biomet Holdings released its earnings results on Aug 05, 2026. The company reported $2.07 earnings per share for the quarter, beating the consensus estimate of $2.01 by $0.06.
Is Zimmer Biomet Holdings overvalued?
According to Wall Street analysts Zimmer Biomet Holdings’s price is currently Undervalued.
Does Zimmer Biomet Holdings pay dividends?
Zimmer Biomet Holdings pays a Quarterly dividend of $0.24 which represents an annual dividend yield of 1.02%. See more information on Zimmer Biomet Holdings dividends here
What is Zimmer Biomet Holdings’s EPS estimate?
Zimmer Biomet Holdings’s EPS estimate is 1.88.
How many shares outstanding does Zimmer Biomet Holdings have?
Zimmer Biomet Holdings has 193,462,480 shares outstanding.
What happened to Zimmer Biomet Holdings’s price movement after its last earnings report?
Zimmer Biomet Holdings reported an EPS of $2.07 in its last earnings report, beating expectations of $2.01. Following the earnings report the stock price went down -10.574%.
Which hedge fund is a major shareholder of Zimmer Biomet Holdings?
Currently, no hedge funds are holding shares in ZBH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zimmer Biomet Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$100.22 (9.71% Upside)
$100.22 (9.71% Upside)
Blogger Sentiment
Bullish
ZBH Sentiment 83%
Sector Average 64%
Sector Average 64%
Hedge Fund Trend
Increased
By 775.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $413.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.4%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.70%
12-Months-Change
Fundamentals
Return on Equity
1.02%
Trailing 12-Months
Asset Growth
2.42%
Trailing 12-Months
Company Description
Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.
ZBH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented more positive developments than negative ones: solid top‑line growth (reported and organic), an EPS beat and raised EPS and free cash flow guidance, strong cash generation, accelerating performance from strategic acquisitions (Paragon 28) and clear momentum in technology and robotics (Monogram enrollment complete, ROSA/TMINI adoption). Offsetting items include short‑term disruption from the U.S. salesforce transformation and legacy knee transitions, some international go‑to‑market disruption, a one‑time tariff benefit that partially pulled forward upside, and higher interest expense tied to acquisition debt. On balance the company appears to be executing on its strategic priorities while managing expected transitional headwinds.View all ZBH earnings summariesZBH Net sales Breakdown
40.36% Knees
25.43% Hips
26.12% S.E.T
8.09% Technology & Data, Bone Cement and Surgical
ZBH Stock 12 Month Forecast
Average Price Target
$100.22
▲(9.71% Upside)
Technical Analysis
Ownership Overview
0.17% Insiders
46.27% Mutual Funds
2.76% Other Institutional Investors
22.81% Public Companies and
Individual Investors